Abstract:The opioid system is one of the most studied pain relieving systems. Opioid peptides have been studied extensively since their discovery, and many efforts have been dedicated to the determination of their intrinsic nature. However, opioid peptides still suffer from serious limitations including lack of oral activity, short duration of action, poor metabolic stability, and relative inability to cross the blood-brain barrier (BBB). Inspired by the structure-activity studies of opioid peptides, four novel opioid dipeptides were synthesized by introduction of Tyr/Dmt to the N-termius and novel unnatural alpha-methylene-beta-amino acids (Map) to the C-terminus. Their in vitro and in vivo activities were determined and compared. The affinity and selectivity of these dipeptides were evaluated by radioligand binding assay in whole cell preparations from HEK293 cells expressing the delta opioid receptor (MOR) or d opioid receptor (DOR), compound 4 exhibited the highest binding affinity toward MOR, and this compound also showed the most significant MOR selectivity over DOR. Pharmacological activities were evaluated in vitro using isolated guinea pig ileum (GPI) for MOR and mouse vas deferens (MVD) for DOR, and the results of GPI and MVD were in accordance with the binding affinity assays. The antinociceptive activities of the compound 4 were assessed in the mouse tail-flick and writhing test after intracerebroventricular (i.c.v.) administration. In the two tests, compound 4 showed good ability to reduce the thermal pain and the inflammatory pain, respectively. Naloxone significantly reversed the activity of the compound, indicating that opioid receptors were involved in its analgesic effects. The compound 4 was then administered inravenously (i.v.) to determine whether this dipeptide was able to cross the BBB. As a result, compound 4 was effective in both tail-flick and writhing test after i.v. administration. Furthermore, the peripherally restricted opioid antagonist naloxone methiodide did not alter the peptide-induced antinociception. Collectively, these results indicated that compound 4 was able to cross the highly selective BBB and might elicit an analgesic response via a central mechanism. Therefore, compound 4 may be a potential lead compound for future clinical development for pain management.

All-Hydrocarbon Stapled Peptide Multifunctional Agonists at Opioid and Neuropeptide FF Receptors: Highly Potent, Long-Lasting Brain Permeant Analgesics with Diminished Side Effects.

Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects

Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception.

Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities.

Multitarget μ-Opioid Receptor Agonists─Neuropeptide FF Receptor Antagonists Induce Potent Antinociception with Reduced Adverse Side Effects

OFP011 Cyclic Peptide as a Multifunctional Agonist for Opioid/Neuropeptide FF Receptors with Improved Blood-Brain Barrier Penetration

The Multifunctional Peptide DN‐9 Produced Peripherally Acting Antinociception in Inflammatory and Neuropathic Pain Via Μ‐ and Κ‐opioid Receptors

The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via μ- and κ-opioid receptors.

Design and Synthesis of a Novel Series of Opioid Dipeptides and Evaluation of Their Analgesic Effect in Vivo

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

Spinal Administration of the Multi-Functional Opioid/neuropeptide FF Agonist BN-9 Produced Potent Antinociception Without Development of Tolerance and Opioid-Induced Hyperalgesia.

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

MEL-N16: A Series of Novel Endomorphin Analogs with Good Analgesic Activity and a Favorable Side Effect Profile

Novel Cyclic Endomorphin Analogues with Multiple Modifications and Oligoarginine Vector Exhibit Potent Antinociception with Reduced Opioid-like Side Effects

An Analgesic Peptide H-20 Attenuates Chronic Pain Via the PD-1 Pathway with Few Adverse Effects.

BN-9, a Chimeric Peptide with Mixed Opioid and Neuropeptide FF Receptor Agonistic Properties, Produces Nontolerance-Forming Antinociception in Mice.

Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects

PD-1: A New Candidate Target for Analgesic Peptide Design

Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide

Novel chimeric peptides based on endomorphins and ghrelin receptor antagonist produced supraspinal antinociceptive effects with reduced acute tolerance in mice

DN-9:a multifunctional agonist of opioid and neuropeptide FF receptors that produces nontoleranceforming analgesia via peripheral opioid receptors in inflammatory and neuropathic pain models